Aditxt, Inc. Cost of Revenue
Aditxt, Inc. (ADTX) reported Cost of Revenue of $9.29 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-20.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-05-20
- Aditxt, Inc. cost of revenue for the quarter ending 2026-03-31 was $9.29K, a 1165.80% increase year-over-year.
- Aditxt, Inc. cost of revenue for the quarter ending 2025-12-31 was $456.00, a 99.36% decline year-over-year.
- Aditxt, Inc. cost of revenue for the quarter ending 2025-09-30 was $732.00, a 99.84% decline year-over-year.
- Aditxt, Inc. cost of revenue for the quarter ending 2025-06-30 was $1.00K, a 95.66% decline year-over-year.
- Aditxt, Inc. cost of revenue for fiscal 2025 was $2.93K, a 99.53% decline from fiscal 2024.
- Aditxt, Inc. cost of revenue for fiscal 2024 was $627.47K, a 17.09% decline from fiscal 2023.
- Aditxt, Inc. cost of revenue for fiscal 2023 was $756.84K, a 1.30% decline from fiscal 2022.
- Aditxt, Inc. cost of revenue for fiscal 2022 was $766.78K.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-03-31 | $9.29K 10-Q · filed 2026-05-20 | $9.75K derived: sum of 2 quarters · filed 2026-05-20 | $10.48K derived: sum of 3 quarters · filed 2026-05-20 | $11.48K derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-12-31 | $456.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.19K derived: sum of 2 quarters · filed 2026-03-31 | $2.19K derived: sum of 3 quarters · filed 2026-03-31 | $2.93K 10-K · filed 2026-03-31 |
| 2025-09-30 | $732.00 10-Q · filed 2025-11-18 | $1.74K derived: sum of 2 quarters · filed 2025-11-18 | $2.47K 10-Q · filed 2025-11-18 | $73.48K derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-06-30 | $1.00K 10-Q · filed 2025-08-14 | $1.74K 10-Q · filed 2025-08-14 | $72.74K derived: sum of 3 quarters · filed 2026-05-20 | $540.28K derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-03-31 | $734.00 10-Q · filed 2026-05-20 | $71.74K derived: sum of 2 quarters · filed 2026-05-20 | $539.27K derived: sum of 3 quarters · filed 2026-05-20 | $562.41K derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | $71.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $538.54K derived: sum of 2 quarters · filed 2026-03-31 | $561.67K derived: sum of 3 quarters · filed 2026-03-31 | $627.47K 10-K · filed 2026-03-31 |
| 2024-09-30 | $467.54K 10-Q · filed 2025-11-18 | $490.67K derived: sum of 2 quarters · filed 2025-11-18 | $556.47K 10-Q · filed 2025-11-18 | $842.34K derived: sum of 4 quarters · filed 2025-11-18 |
| 2024-06-30 | $23.13K 10-Q · filed 2025-08-14 | $88.93K 10-Q · filed 2025-08-14 | $374.80K derived: sum of 3 quarters · filed 2025-08-14 | $481.72K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $65.80K 10-Q · filed 2025-05-15 | $351.67K derived: sum of 2 quarters · filed 2025-05-15 | $458.59K derived: sum of 3 quarters · filed 2025-05-15 | $644.33K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $285.87K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $392.79K derived: sum of 2 quarters · filed 2025-03-31 | $578.53K derived: sum of 3 quarters · filed 2025-03-31 | $756.84K 10-K · filed 2025-03-31 |
| 2023-09-30 | $106.92K 10-Q · filed 2024-11-18 | $292.66K derived: sum of 2 quarters · filed 2024-11-18 | $470.97K 10-Q · filed 2024-11-18 | |
| 2023-06-30 | $185.74K 10-Q · filed 2024-08-19 | $364.05K 10-Q · filed 2024-08-19 | ||
| 2023-03-31 | $178.31K 10-Q · filed 2024-05-20 | |||
| 2022-12-31 | $766.78K 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |